Analysis of nitric oxide (NO) in cerebral vasospasm after aneursymal bleeding

Reviews on Recent Clinical Trials

Volumn 2, Issue 1, 2007, Pages 59-67

  Pluta, Ryszard M ^a   Oldfield, Edward H ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

ADMA; Donors; Nitric oxide; NO; SAH; Sodium nitrite; Vasospasm

Indexed keywords

1 [6 CHLORO 4 (3,4 METHYLENEDIOXYBENZYLAMINO) 2 QUINAZOLINYL] 4 PIPERIDINECARBOXYLIC ACID; ALTEPLASE; BIPYRIDINE; DIMETHYLARGININASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTROGEN; GLYCERYL TRINITRATE; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LINSIDOMINE; METHEMOGLOBIN; N ACETYL S NITROSOPENICILLAMINE; N(G),N(G) DIMETHYLARGININE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE; NITRITE; NITROPRUSSIDE SODIUM; OXYHEMOGLOBIN; PAPAVERINE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROBUCOL; RETINOIC ACID; S NITROSOGLUTATHIONE; SCH 51866; SILDENAFIL; SODIUM NITRITE; UNCLASSIFIED DRUG;

ANEURYSM RUPTURE; ARTERY STEAL SYNDROME; BRAIN BLOOD FLOW; BRAIN VASOSPASM; CANCER RISK; CEREBROSPINAL FLUID DRAINAGE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG TREATMENT FAILURE; ENDOTHELIAL DYSFUNCTION; ERECTILE DYSFUNCTION; HUMAN; HYPERTENSION; HYPOTENSION; IRON CHELATION; LOW DRUG DOSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RESPIRATORY DISTRESS; REVIEW; SUBARACHNOID HEMORRHAGE; THROMBOCYTE AGGREGATION INHIBITION; TUMOR GROWTH;

HUMANS; INTRACRANIAL ANEURYSM; NITRIC OXIDE; NITRIC OXIDE DONORS; SUBARACHNOID HEMORRHAGE; VASOSPASM, INTRACRANIAL;

EID: 34248184166     PISSN: 15748871     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488707779318062     Document Type: Review

References (166)

1. Kassell NF, Torner JC. The International Cooperative Study in timing of aneurysm surgery-an update. Stroke 1984; 15: 566-570.
2. Schievink W. Intracranial aneurysms. NEJM 1997; 336: 28-40.
3. Stapf C, Mohr J. Aneurysms and subarachnoid hemorrhage-epidemiology. In: PD Le Roux HW, DW Newell, editor. Management of cerebral aneurysms. Philadelphia, PA: Elsevier Inc; 2004; pp. 183-187.
4. Weir B, Grace M, Hansen J, Rothberg C. Time course of vasospasm in man. J Neurosurg 1978; 48: 173-178.
5. Gull W. Cases of aneurism of the cerebral vessels. Guy's Hosp Rep 1859; 5: 281-304.
6. Ecker A, Rimenschneider P. Arteriographic demonstration of spasm of the intracranial arteries with special reference to saccular arterial aneurysms. J Neurosurg 1951; 8: 660-667.
7. Asano T. Oxyhemoglobin as the principal cause of cerebral vasospasm: a holistic view of its actions. Crit Rev Neurosurg 1999; 9: 303-318.
8. Crompton M. The pathogenesis of cerebral infarction following the rupture of cerebral berry aneurysms. Brain 1964; 87: 491-510.
9. Macdonald R, Weir B. A review of hemoglobin and the pathogenesis of cerebral vasospasm. Stroke 1991; 22: 971-982.
10. Ohta T, Kajikawa H, Yoshikawa Y, et al. Cerebral vasospasm and hemoglobins: Clinical and experimental studies. In: Wilkins RH, editor. Cerebral Arterial Spasm. Baltimore/London: Williams & Wilkins; 1980; pp. 166-172.
11. Furchgott R, Zawadzki J. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-376.
12. Ignarro L. Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu Rev Pharmacol Toxicol 1990; 30: 535-560.
13. Liu X, Miller M, Joshi H, Sadowska-Krowicka H, Clark D, Lancaster J. Diffusion-limited reaction of free nitric oxide with erythrocytes. J Biol Chem 1998; 273: 18709-18713.
14. Afshar J, Pluta R, Boock R, Thompson B, Oldfield E. Effect of intracarotid nitric oxide on primate cerebral vasospasm after subarachnoid hemorrhage. J Neurosurg 1995; 83: 118-122.
15. Brown F, Hanlon K, Crockard H, Mullan S. Effect of sodium nitroprusside on cerebral blood flow in conscious human beings. Surg Neurol 1977; 7:67-70.
16. Dorsch N. Therapeutic approaches to vasospasm in subarachnoid hemorrhage. Curr Opin Crit Care 2002; 8: 128-133.
17. Jung C, Iuliano B, Harvey-White J, Espey M, Oldfield EH, Pluta RM. Association between cerebrospinal fluid levels of asymmetric dimethyl-L-arginine, an endogenous inhibitor of endothelial nitric oxide synthase, and cerebral vasospasm in a primate model of subarachnoid hemorrhage. J Neurosurg 2004; 101:836-842.
18. Kiris T, Karasu A, Yavuz C, et al. Reversal of cerebral vasospasm by the nitric oxide donor SNAP in an experimental model of subarachnoid haemorrhage. Acta Neurochir (Wien) 1999; 141: 1323-1328.
19. Kistler J, Lees R, Candia G, Zervas N, Crowell R, Ojemann R. Intravenous nitroglycerin in experimental vasospasm. A preliminary report. Stroke 1979; 10: 26-29.
20. Macdonald RL, Zhang Z-D, Curry D, et al. Intracisternal sodium nitroprusside fails to prevent vasospasm in nonhuman primates. Neurosurgery 2002; 51(3): 761-770.
21. Ng W, Moochhala S, Yeo T, Ong P, Ng P. Nitric oxide and subarachnoid hemorrhage: Elevated levels in cerebrospinal fluid and their implications. Neurosurgery 2001; 49: 622-627.
22. Nishizawa S, Yamamoto S, Yokoyama T, Uemura K. Dysfunction of nitric oxide synthase induces protein kinase C activation resulting in vasospasm after subarachnoid hemorrhage. Neurol Res 1997; 19: 558-562.
23. Ohkita M, Takaoka M, Shiota Y, Nojiri R, Matsumura Y. Nitric oxide inhibits endothelin-1 production through the suppression of nuclear factor kappa B. Clin Sci (London) 2002; 103 (Suppl 48): 68S-71S.
24. Pluta R, Oldfield E, Boock R. Reversal and prevention of cerebral vasospasm by intracarotid infusions of nitric oxide donors in a primate model of subarachnoid hemorrhage. J Neurosurg 1997; 87: 746-751.
25. Pluta RM, Dejam A, Grimes G, Gladwin MT, Oldfield EH. Nitrite infusions prevent cerebral artery vasospasm in a primate model of subarachnoid aneurismal hemorrhage. JAMA 2005; 293:1477-1484.
26. Sehba F, Chereshnev I, Maayani S, Friedrich Jr V, Bederson J. Nitric oxide synthase in acute alteration of nitric oxide levels after subarachnoid hemorrhage. Neurosurgery 2004; 55:671-678.
27. Sobey C. Cerebrovascular dysfunction after subarachnoid hemorrhage: Novel mechanisms and directions for therapy. Clin Exp Pharm Physiol 2001; 28: 926-929.
28. Stoodley M, Weihl C, Zhang Z, et al. Effect of adenovirus-mediated nitric oxide synthase gene transfer on vasospasm after experimental subarachnoid hemorrhage. Neurosurgery 2000; 46: 1193-1203.
29. Suzuki Y, Kajita Y, Oyama H, et al. Dysfunction of nitric oxide in the spastic basilar arteries after subarachnoid hemorrhage. J Auton Nerv Syst 1994; 49 (Suppl): S83-87.
30. Suzuki Y, Osuka K, Noda A, et al. Nitric oxide metabolites in the cisternal cerebral spinal fluid in patients with subarachnoid hemorrhage. Neurosurgery 1997; 41: 807-812.
31. Thomas J, Nemirovsky A, Zelman V, Giannotta S. Rapid reversal of endothelin-1-induced vasoconstriction by intrathecal administration of nitric oxide donor. Neurosurgery 1997; 40: 1245-1249.
32. Toda N, Okamura T. Possible role of nitric oxide in transmitting information from vasodilator nerve to cerebroarterial muscle. Biochem Biophys Res Commun 1990; 170: 308-313.
33. Widenka D, Medele R, Stummer W, Bise K, Steiger H. Inducible nitric oxide synthase: a possible key factor in the pathogenesis of chronic vasospasm after experimental subarachnoid hemorrhage. J Neurosurg 1999; 90: 1098-1104.
34. Buchanan J, Philis J. The role of nitric oxide in the regulation of cerebral blood flow. Brain Res 1993; 610: 248-255.
35. Dirnagl U, Lindauer U, Villringer A. Role of nitric oxide coupling of cerebral blood flow to neuronal activation in rats. Neurosci Lett 1992; 149: 43-46.
36. Thompson BG, Pluta RM, Girton M, Oldfield EH. Nitric oxide mediation of chemoregulation but not autoregulation of cerebral blood flow in primates. J Neurosurg 1996; 84: 71-78.
37. Watkins L. Nitric oxide and cerebral blood flow: An update. Cerebrovasc Brain Metabol Rev 1995; 7: 324-337.
38. Zhang F, White J, Iadecola C. Nitric Oxide donors increase blood flow and reduce brain damage in focal ischemia: Evidence that nitric oxide is beneficial in the early stages of cerebral ischemia. J Cereb Blood Flow Metab 1994; 14: 217-226.
39. Pluta R, Thompson B, Dawson T, Snyder S, Oldfield E. Loss of Nitric Oxide synthase immunoreactivity in cerebral vasospasm. J Neurosurg 1996; 84: 648-654.
40. Iuliano B, Pluta R, Jung C, Oldfield E. Endothelial dysfunction in a primate model of cerebral vasospasm. J Neurosurg 2004; 100: 287-294.
41. Gabikian P, Clatterbuck R, Eberhart C, Tyler B, Tierney T, Tamargo R. Prevention of experimental cerebral vasospasm by intracranial delivery of a nitric oxide donor from a controlled-release polymer: toxicity and efficacy studies in rabbits and rats. Stroke 2002; 33: 2681-6.
42. Morikawa E, Huang Z, Rosenblatt S, Yoshida T, Moskowitz M. Therapeutic potential of L-arginine, a precursor of Nitric Oxide, in focal cerebral ischemia. In: Bevan J, Bevan R, editors. The human brain circulation. Totowa, NJ: Humana Press; 1994; pp. 373-387.
43. Nakao K, Murata H, Kanamaru K, Waga S. Effects of nitroglycerin on vasospasm and cyclic nucleotides in a primate model of subarachnoid hemorrhage. Stroke 1996; 27: 1882-7.
44. Pluta R, Afshar J, Thompson B, Boock R, Harvey-White J, Oldfield E. L-arginine increases cerebral blood flow but does not reverse or prevent vasospasm after subarachnoid hemorrhage. J Neurosurg 2000; 92: 121-126.
45. Pradilla G, Thai Q, Legnani F, et al. Delayed intracranial delivery of a nitric oxide donor from a controlled-release polymer prevents experimental cerebral vasospasm in rabbits. Neurosurgery 2004; 2004: 1393-9.
46. Thomas J, Rosenwasser R. Reversal of severe cerebral vasospasm in three patients after aneurysmal subarachnoid hemorrhage: initial observations regarding the use of intraventricular sodium nitroprusside in humans. Neurosurgery 1999; 44(1): 48-57.
47. Vajkoczy P, Hubner U, Horn P, et al. Intrathecal sodium nitroprusside improves cerebral blood flow and oxygenation in refractory cerebral vasospasm and ischemia in humans. Stroke 2000; 31(5): 1195-7.
48. Chen A, Jiang S, Crotty T, et al. Effects of in vivo adventitial expression of recombinant endothelial nitric oxide synthase gene in cerebral arteries. Proc Natl Acad Sci USA 1997; 94: 12568-12573.
49. Luders J, Weihl C, Lin G, et al. Adenoviral gene transfer of nitric oxide synthase increases cerebral blood flow in rats. Neurosurgery 2000; 47: 1206-14.
50. Pluta R, Afshar J, Boock R, Oldfield E. Temporal changes in perivascular concentrations of oxyhemoglobin, deoxyhemoglobin and, methemoglobin in subarachnoid hemorrhage. J Neurosurg 1998; 88: 557-561.
51. Regan R, Panter S. Neurotoxicity of hemoglobin in cortical cell culture. Neurosci Lett 1993; 153: 219-222.
52. Smith R, Louis C, Kruszyna R, Kruszyna H. Acute neurotoxicity of sodium azide and nitric oxide. Toxicol Appl Pharmacol 1991; 17: 120-127.
53. Wang X, Mori T, Sumii T, Lo E. Hemoglobin-induced cytotoxicity in rat cerebral cortical neurons. Caspase activation and oxidative stress. Stroke 2002; 33: 1882-1888.
54. Buga G, Gold M, Fukuto J, Ignarro L. Shear stress-induced release of nitric oxide from endothelial cells grown on beads. Hypertension 1991; 17: 187-193.
55. Gaw A, Bevan J. Flow-induced relaxation of the rabbit middle cerebral artery is composed of both endothelium-dependent and - independent components. Stroke 1993; 24: 105-110.
56. Rubanyi G, Romero J, Vanhoutte P. Flow-induced release of endothelium-derived relaxing factor. Am J Physiol 1988; 250: H1145-H1149.
57. Xiao Z, Zhang Z, Diamond S. Shear stress induction of endothelial nitric oxide synthase gene is calcium-dependent but not calcium-activated. J Cell Physiol 1997; 171: 205-211.
58. Hoffmann J, Dimmeler S, Haendeler J. Shear stress increases the amount of S-nitrosylated molecules in endothelial cells: important role for signal transduction. FEBS Lett 2003; 551: 153-158.
59. Ignarro L. Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. J Physiol Pharmacol 2002; 53: 503-14.
60. Kasuya H, Weir B, Nakane M, et al. Nitric oxide synthase and guanylate cyclase levels in canine basilar artery after subarachnoid hemorrhage. J Neurosurg 1995; 82: 250-255.
61. Sakowitz O, Wolfrum S, Sarrafzadeh A, et al. Relation of cerebral energy metabolism and extracellular nitrite and nitrate concentration in patients after aneurysmal subarachnoid hemorrhage. J Cereb Blood Flow Metabol 2001; 21: 1067-1076.
62. Clark J, Reilly M, Sharp F. Oxidation of bilirubin produces compounds that cause prolonged vasospasm of rat cerebral vessels: A contributor to subarachnoid hemorrhage-induced vasospasm. J Cereb Blood Flow Metab 2002; 22: 472-478.
63. Pyne-Geithman G, Morgan C, Wagner K, et al. Bilirubin production and oxidation in CSF of patients with cerebral vasospasm after subarachnoid hemorrhage. J Cereb Blood Flow Metab 2005; 25: 1070-7.
64. Macdonald R, Weir B. Cerebral vasospasm. In. San Diego: Academic Press; 2001; pp. 449-450.
65. Wilkins R. Attempts at prevention or treatment of intracranial arterial spasm: An update. Neurosurgery 1986; 18: 808-825.
66. Findlay J, Weir B, Steinke D, Tanabe T, Gordon P, Grace M. Effect of intrathecal thrombolytic therapy on subarachnoid clot and chronic vasospasm in primate model of SAH. J Neurosurg 1988; 69: 723-735.
67. Handa Y, Weir B, Nosko M, Mosewich R, Tsuji T, Grace M. The effect of timing of clot removal on chronic vasospasm ina primate model. J Neurosurg 1987; 67: 558-564.
68. Klimo P, Kestle J, MacDonald J, Schmidt R. Marked reduction of cerebral vasospasm with lumbar drainage of cerebrospinal fluid after subarachnoid hemorrhage. J Neurosurg 2004; 100: 215-24.
69. Horky L, Pluta R, Boock R, Oldfield E. Ferrous iron chelator 2.2′-dipyridyl prevents delayed vasospasm in a primate model of subarachnoid hemorrhage. J Neurosurg 1998; 88: 298-303.
70. Toda N, Ayajiki K, Tanaka T, Okamura T. Preganglionic and postaganglionic neurons responsible for cerebral vasodilation mediated by nitric oxide in anesthetized dogs. J Cereb Flow Metab 2000; 20: 700-708.
71. Doyle M, Hoekstra J. Oxidation of nitrogen oxides by bound dioxygen in hemoproteins. J Inorg Biochem 1981; 14: 351-8.
72. Gladwin M, Wang X, Reiter C, et al. S-Nitrosohemoglobin is unstable in the reductive erythrocyte environment and lacks O2/NO-linked allosteric function. J Biol Chem 2002; 277: 27818-28.
73. Stamler JS, Jaraki O, Osborne J, et al. Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc Natl Acad Sci USA 1992; 89(16): 7674-7.
74. Marsh N, Marsh A. A short history of nitroglycerine and nitric oxide in pharmacology and physiology. Clin Exp Pharmacol Physiol 2000; 27(4): 313-9.
75. Frazee JG, Giannotta SL, Stern ES. Intravenous nitroglycerin for the treatment of chronic cerebral vasoconstriction in the primate. J. Neurosurg 1981; 55: 865-868.
76. Heros R, Zervas N, Lavyne M, Pickren K. Reversal of experimental cerebral vasospasm by intravenous nitroprusside therapy. Surg Neurol 1976; 6: 227-229.
77. Katsuki S, Arnold W, Mittal C, Murad F. Stimulation of guanylate cyclase by sodium nitroprusside, nitroglycerin and nitric oxide in various tissue preparations and comparison to the effects of sodium azide and hydroxylamine. J Cyclic Nucleotide Res 1977; 3(1): 23-35.
78. Egemen N, Turker RK, Sanlidilek U, et al. The effect of intrathecal sodium nitroprusside on severe chronic vasospasm. Neurol Res 1993; 15(5): 310-5.
79. Ito Y, Isotani E, Mizuno Y, Azuma H, Hirakawa K. Effective improvement of the cerebral vasospasm after subarachnoid hemorrhage with low-dose nitroglycerin. J Cardiovasc Pharmacol 2000; 35: 45-50.
80. Allen G. Cerebral arterial spasm: Part 8. The treatment of delayed cerebral arterial spasm in human beings. Surg Neurol 1976; 6: 71-80.
81. Paulson O. Regional cerebral blood flow in appoplexy due to occlusion of the middle cerebral artery. Neurology 1970; 20: 63-77.
82. Blaumanis O, Grady P, Nelson E. Hemodynamic and morphologic aspects of cerebral vasospasm. In: Price T, Nelson E, editors. Cerebrovascular diseases. New York: Raven Press; 1979; pp. 283-294.
83. Aaslid R. Cerebral Hemodynamics. In: Newell D, Aaslid R, editors. Transcranial Doppler. New York: Raven Press; 1992; pp. 49-55.
84. Hashi K, Mayer J, Shinmaru S, Welch K, Teraura T. Cerebral hemodynamic and metabolic changes after subarachnoid hemorrhage. J Neurol Sci 1972; 17: 1-14.
85. Steinmeier R, Laumer R, Bondar I, Priem R, Fahlbush R. Cerebral hemodynamics in subarachnoid hemorrhage evaluated by Transcranial Doppler sonography. Part 2. Pulsatility Indices: Normal reference values and characteristics in subarachnoid hemorrhage. Neurosurgery 1993; 33: 10-19.
86. Ram Z, Spiegelman R, Findler G, Hadani M. Delayed postoperative neurological deterioration from prolonged sodium nitroprusside administration. Case report. J Neurosurg 1989; 71(4): 605-7.
87. Saavedra J, Southan G, Davies K, et al. Localizing antithrombotic and vasodilatory activity with a novel, ultrafast nitric oxide donor. J Med Chem 1996; 39: 4361-4365.
88. Moniz E. Scientific raisins from 125 years SMW (Swiss Medical Weekly). Clinical and physiological results of cerebral angiography. 1935. Schweiz Med Wochenschr 1995; 125: 1503-7.
89. Dedrick RL, Oldfield EH, Collins JM. Arterial Drug Infusion with Extracorporeal Removal I. Theoretical Basis with Particular Reference to the Brain. Cancer Treat Rep 1984; 68: 373-380.
90. Dedrick RL. Arterial drug infusion: pharmacokinetic problems and pitfalls. J Natl Cancer Inst 1988; 80(2): 84-9.
91. Kassell N, Helm G, Simmons N, Phillips C, Cail W. Treatment of cerebral vasospasm with intra-arterial papaverine. J Neurosurg 1992; 77: 848-852.
92. Morgan M, Jonker B, Finfer S, Harrington T, Dorsch NW. Aggressive management of aneurysmal subarachnoid haemorrhage based on a papaverine angioplasty protocol. J Clin Neurosci 2000; 7: 305-308.
93. Polin R, Hansen C, German P, Chadduck J, Kassell N. Intra-arterial papaverine administered for the treatment of symptomatic cerebral vasospasm. Neurosurgery 1998; 42: 1256-1267.
94. Weyerbrock A, Walbridge S, Pluta RM, Saavedra JE, Keefer LK, Oldfield EH. Selective opening of the blood-tumor barrier by a nitric oxide donor and long-term survival in rats with C6 gliomas. J Neurosurg 2003; 99(4): 728-37.
95. Singh R, Hogg H, Joseph J, et al. The peroxynitrate generator, SIN-1, becomes a nitric oxide donor in the presence of electron acceptors. Arch Bioch Biophys 1999; 361: 331-9.
96. Sehba FA, Ding WH, Chereshnev I, Bederson JB. Effects of S-nitrosoglutathione on acute vasoconstriction and glutamate release after subarachnoid hemorrhage. Stroke 1999; 30(9): 1955-61.
97. Wink D, Cook J, Pacelli R, DeGraff W, Gamson J, Krishna M, et al. Effect of various nitric oxide-donor agents on peroxide mediated toxicity. A direct correlation between nitric oxide formation and protection. Arch Biochem Biophys 1996; 331: 241-248.
98. Smith DJ, Chakravarthy D, Pulfer S, et al. Nitric oxide-releasing polymers containing the [N(O)NO]- group. J Med Chem 1996; 39(5): 1148-56.
99. Aihara Y JB, Yassari R, Sayama T, Macdonald RL. Effects of a nitric oxide donor on and correlation of changes in cyclic nucleotide levels with experimental vasospasm. Neurosurgery 2003; 52: 661-667.
100. Tierney T, Pradilla G, Wang P, Clatterbuck RE, Tamargo R. Intracranial Delivery of the Nitric Oxide Donor Diethylenetriamine/Nitric Oxide from a Controlled-Release Polymer: Toxicity in Cynomolgus Monkeys. Neurosurgery 2006; 58: 952-960.
101. Zhang R, Zhang L, Zhang Z. A nitric oxide donor induces neurogenesis and reduces functional deficits after stroke in rats. Ann Neurol 2001; 50: 602-611.
102. Raabe A, Zimmermann M, Setzer M, Vatter H, Berkefeld J, Seifert V. Effect of intraventricular sodium nitroprusside on cerebral hemodynamics and oxygenation in poor-grade aneurysm patients with severe, medically refractory vasospasm. Neurosurgery 2002; 50: 1006-13.
103. Wolf EW, Banerjee A, Soble-Smith J, Dohan FC, Jr., White RP, Robertson JT. Reversal of cerebral vasospasm using an intrathecally administered nitric oxide donor. J Neurosurg 1998; 89(2): 279-88.
104. Clatterbuck RE GP, Tierney T, Clatterbuck VM, Murphy KJ, Tamargo RJ. Controlled release of a nitric oxide donor for the prevention of delayed cerebral vasospasm following experimental subarachnoid hemorrhage in nonhuman primates. J Neurosurg 2005; 103: 745-51.
105. Hanel R, Lopes D, Wehman J, et al. Endovascular treatment of intracranial aneurysms and vasospasm after aneurysmal subarachnoid hemorrhage. Neurosurg Clin N Am 2005; 16: 317-53.
106. Gladwin M, Crawford J, Patel R. The biochemistry of nitric oxide, nitrite, and hemoglobin: role in blood flow regulation. Free Rad Biol Med 2004; 36: 707-716.
107. Rassaf T, Preik M, Kleinbongard P, et al. Evidence for in vivo transport of bioactive nitric oxide in human plasma. J Clin Invest 2002; 109(9): 1241-8.
108. Cosby K, Partovi K, Crawford J, et al. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nature Medicine 2003(9): 1498-1505.
109. Lauer T, Preik M, Rassaf T, et al. Plasma nitrite rather than nitrate reflects regional endothelial nitric oxide synthase activity but lacks intrinsic vasodilator action. Proc Natl Acad Sci USA 2001; 98: 12814-9.
110. Luchsinger B, Rich E, Yan Y, Williams E, Stamler J, Singel D. Assessment of the chemistry and vasodilatory activity of nitrite with hemoglobin under physiologically relevant conditions. J Inorg Biochem 2005; 99: 912-921.
111. Rassaf T, Kleinbongard P, Preik M, et al. Plasma nitrosothiols contribute to the systemic vasodilator effects of intravenously applied NO: experimental and clinical study on the fate of NO in human blood. Circ Res 2002; 91: 470-477.
112. Stitt M, Fernie A. From measurements of metabolites to metabolomics: an 'on the fly' perspective illustrated by recent studies of carbon-nitrogen interactions. Curr Opin Biotechnol 2003; 14: 136-44.
113. Duranski M, Greer J, Dejam A, et al. Cytoprotective effects of nitrite during ischemia-reperfusion of the heart and liver. JCI 2005; 115: 1232-40.
114. Hunter C, Dejam A, Blood A, et al. Inhaled nebulized nitrite is a hypoxia-sensitive NO-dependcnt selective pulmonary vasodilator. Nat Med 2004; 10: 1122-7.
115. Bryan N, Rassaf T, Maloney R, et al. Cellular targets and mechanism of nitros(yl)ation: An insight into their nature and kinetics in vivo. Proc Natl Aacd Sci USA 2004; 101: 4308-4313.
116. Burmester T, Ebner B, Weich B, Hankeln T. Cytoglobin: a novel globin type ubiquitously expressed in vertebrate tissues. Mol Biol Evol 2002; 19(4): 416-21.
117. Burmester T, Hankeln T. Neuroglobin: a respiratory protein of the nervous system. News Physiol Sci 2004; 19: 110-3.
118. Kugelstadt D, Haberkamp M, Hankeln T, Burmester T. Neuroglobin, cytoglobin, and a novel, eye-specific globin from chicken. Biochem Biophys Res Commun 2004; 325(3): 719-25.
119. Nagababu E, Ramasamy S, Abernethy D, Rifkind J. Active nitric oxide produced in the red cell under hypoxic conditions by deoxyhemoglobin-mediated nitrite reduction. J Biol Chem 2003; 278: 46349-56.
120. Sambrook M, Hutchinson E, Aber G. Metabolic studies in subarachnoid haemorrhage and strokes. I. Serial changes in acid-base values in blood and cerebrospinal fluid. Brain 1973; 96: 171-90.
121. Smith R. Ever so cautiously, the FDA moves toward a ban on nitrites. Science 1978; 201: 887-891.
122. Smith R. Nitrites: FDA beats a surprising retreat. Science 1980; 209: 1100-1101.
123. Iadecola C, Pelligrino D, Moskowitz M, Larsen N. State of the art review. Nitric oxide synthase inhibition and cerebrovascular regulation. J Cereb Blood Flow Metabol 1994; 14: 175-192.
124. Newberne PM. Nitrite promotes lymphoma incidence in rats. Science 1979; 204(4397): 1079-81.
125. Soderberg L. Increased tumor growth in mice exposed to inhaled isobutyl nitrite. Toxicol Lett 1999; 104: 35-41.
126. Huncharek M, Kupelnick B. A meta-analysis of maternal cured meat consumption during pregnancy and the risk of childhood brain tumors. Neuroepidemiology 2004; 23(1-2): 78-84.
127. McKean-Cowdin R, Pogoda JM, Lijinsky W, Holly EA, Mueller BA, Preston-Martin S. Maternal prenatal exposure to nitrosatable drugs and childhood brain tumours. Int J Epidemiol 2003; 32(2): 211-7.
128. Chen H, Ward MH, Tucker KL, et al. Diet and risk of adult glioma in eastern Nebraska, United States. Cancer Causes Control 2002; 13(7): 647-55.
129. Tran DC, Yeh KC, Brazeau DA, Fung HL. Inhalant nitrite exposure alters mouse hepatic angiogenic gene expression. Biochem Biophys Res Commun 2003; 310(2): 439-45.
130. Gallo O, Masino E, Morbidelli L, et al. Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst 1998; 90: 587-596.
131. Duda D, Fukumura D, Jain R. Role of eNOS in neovascularization: NO for endothelial progenitor cell. Trends Mol Med 2004; 10: 143-5.
132. Fukumura D, Gohongi T, Kadambi A, et al. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci USA 2001; 98: 2604-2609.
133. Garcia-Cardena G, Folkman J. Is there a role for Nitric oxide in tumor angiogenesis. J NCI 1998; 90: 560-561.
134. Pipili-Synetos E, Papageorgious A, Sakkoula E, et al. Inhibition of angiogenesis, tumour growth and metastasis by the NO-releasing vasodilators, isosorbide mononitrate and dinitrate. Br J Pharmacol 1995; 116: 1829-1834.
135. Bredt D, Snyder S. Nitric oxide, a novel neuronal messenger. Neuron 1992; 8: 3-11.
136. Moncada S, Higgs EA. The discovery of nitric oxide and its role in vascular biology. Br J Pharmacol 2006; 147 (Suppl 1): S193-201.
137. Vallance P, Chan N. Endothelial dysfunction and nitric oxide: clinical relevance. Heart 2001; 85: 342-350.
138. Leiper J, Murray-Rust J, McDonald N, Vallance P. S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminehydrolase. Proc Natl Acad Sci USA 2002; 99: 13527-32.
139. Boger R, Sydow K, Borlak J, et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosyl-methionine-dependent methyl-transferases. Circ Res 2000; 87: 99-105.
140. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al. Effects of 3-hyrdoxy-3-methylglutaryl-CoA reductase inhibitors, Atarvostatin and Simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. JCI 1998; 101: 2711-2719.
141. Sawayama Y, Shimizu C, Maeda N, et al. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia: Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol 2002; 39: 610-616.
142. Dobrucki LW, Kalinowski L, Dobrucki IT, Malinski T. Statin-stimulated nitric oxide release from endothelium. Med Sci Monit 2001; 7(4): 622-7.
143. McGirt M, Pradilla G, Legnani F, et al. Systemic administration of simvastatin after the onset of experimental subarachnoid hemorrhage attenuates cerebral vasospasm. Neurosurgery 2006; 58: 945-951.
144. McGirt MJ, Lynch J, Parra A, et al. Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm resulting from subarachnoid hemorrhage. Stroke 2002; 33: 2950-2956.
145. Tseng M-Y, Czosnyka M, Richards H, Pickard J, Kirkpatrick P. Effects of Acute Treatment With Pravastatin on Cerebral Vasospasm, Autoregulation, and Delayed Ischemic Deficits After Aneurysmal Subarachnoid Hemorrhage: A Phase II Randomized Placebo-Controlled Trial. Stroke 2005; 36: 1627-1632.
146. Lynch JR, Wang H, McGirt MJ, et al. Simvastatin reduces vasospasm after aneurysmal subarachnoid hemorrhage: results of a pilot randomized clinical trial. Stroke 2005; 36(9): 2024-6.
147. Parra A, Kreiter KT, Williams S, et al. Effect of prior statin use on functional outcome and delayed vasospasm after acute aneurysmal subarachnoid hemorrhage: a matched controlled cohort study. Neurosurgery 2005; 56(3): 476-84.
148. Lau A, Leichtweis S, Hume P, et al. Probucol promotes functional reendothelization in balloon-injured rabbit aortas. Circulation 2003; 107: 2031-2036.
149. Jiang J-L, L N-S, Deng H-W. Probucol preserves endothelial function by reduction of the endogenous nitric oxide synthase inhibitor level. Br J Pharmacol 2002; 135: 1175-1182.
150. Pluta R, Jung C, Shilad S, Whitehead A, Espey M, Odfield E. Probucol does not inhibit production of ADMA or prevent vasospasm in randomized, blind placebo-controlled trial in a primate model of vasospasm. J. Neurosurg 2005; 103: 731-738.
151. Lauer T, Kleinbongard P, Kelm M. Indexes of NO bioavailability in human blood. News Physiol Sci 2002; 17: 251-255.
152. Kleinbongard P, Dejam A, Lauer T, et al. Plasma nitrite reflects constitutive nitric oxide synthase activitiy in mammals. Free Radical Biol Med 2003; 35: 790-796.
153. Zweier J, Wang P, Samouilov A, Kuppusamy P. Enzyme-independent formation of nitric oxide in biological tissues. Nature Med 1995; 1: 804-809.
154. Achan V, Tran C, Arrigoni F, Whitley G, Leiper L, Vallance P. All-trans-retinoic acid increases nitric oxide synthesis by endothelial cells. A role for the induction of dimethylarginine dimethylaminohydrolase. Circ Res 2002; 90: 764-769.
155. Holden D, Cartwright J, Nussey S, Whitley G. Estrogen stimulates DDAH activity and the metabolism of ADMA. Circulation 2003; 108: 1575-1580.
156. Adachi H, Nishino M. Coronary artery diameter increase induced by a phosphodiesterase 5 inhibitor, E4021, in conscious pigs. Jpn J Pharmacol 1998; 77: 99-102.
157. Andrianne R. [Drug of the month. Sildenafil (Viagra)] [Article in French]. Rev Med Liege 1999; 54: 58-61.
158. Chiu PJ, Vemulapalli S, Chintala M, et al. Inhibition of platelet adhesion and aggregation by E4021, a type V phosphodiesterase inhibitor, in guinea pigs. Naunyn Schmiedebergs Arch Pharmacol 1997; 355(4): 463-9.
159. Dukarm RC, Russell JA, Morin FC, 3rd, Perry BJ, Steinhorn RH. The cGMP-specific phosphodiesterase inhibitor E4021 dilates the pulmonary circulation. Am J Respir Crit Care Med 1999; 160(3): 858-65.
160. Ohnishi M, Oka M, Muramatsu M, Sato K, Kira S, Fukuchi Y. E4021, a selective phosphodiesterase 5 inhibitor, potentates the vasodilator effect of inhaled nitric oxide in isolated perfused rat lungs. J Cardiovasc Pharmacol 1999; 33(4): 619-24.
161. Oka M. Phosphodiesterase 5 inhibition restores impaired ACh relaxation in hypertensive conduit pulmonary arteries. Am J Physiol Lung Cell Mol Physiol 2001; 280: L432-5.
162. Saeki T, Adachi H, Takase Y, Yoshitake S, Souda S, Saito I. A selective type V phosphodiesterase inhibitor, E4021, dilates porcine large coronary artery. J Pharmacol Exp Ther 1995; 272(2): 825-31.
163. Thompson W, Piazza G, Li H, et al. Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res 2000; 60: 3338-42.
164. Vemulapalli S, Watkins R, Chintala M, et al. Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor. J Cardiovasc Pharmacol 1996; 28: 862-9.
165. Birk S, Kruuse C, Petersen KA, Jonassen O, Tfelt-Hansen P, Olesen J. The phosphodiesterase 3 inhibitor cilostazol dilates large cerebral arteries in humans without affecting regional cerebral blood flow. J Cereb Blood Flow Metab 2004; 24(12): 1352-8.
166. Inoha S, Inamura T, Ikezaki K, Nakamizo A, Amano T, Fukui M. Type V phosphodiesterase expression in cerebral arteries with vasospasm after subarachnoid hemorrhage in a canine model. Neurol Res 2002; 24(6): 607-12.